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Abstract
Background: Consent forms have lengthened over time and become harder for participants to understand. We sought to
demonstrate the feasibility of creating a simplified consent form for biobanking that comprises the minimum information
necessary to meet ethical and regulatory requirements. We then gathered preliminary data concerning its content from
hypothetical biobank participants.
Methodology/Principal Findings: We followed basic principles of plain-language writing and incorporated into a 2-page
form (not including the signature page) those elements of information required by federal regulations and recommended
by best practice guidelines for biobanking. We then recruited diabetes patients from community-based practices and
randomized half (n=56) to read the 2-page form, first on paper and then a second time on a tablet computer. Participants
were encouraged to use ‘‘More information’’ buttons on the electronic version whenever they had questions or desired
further information. These buttons led to a series of ‘‘Frequently Asked Questions’’ (FAQs) that contained additional detailed
information. Participants were asked to identify specific sentences in the FAQs they thought would be important if they
were considering taking part in a biorepository. On average, participants identified 7 FAQ sentences as important (mean 6.6,
SD 14.7, range: 0–71). No one sentence was highlighted by a majority of participants; further, 34 (60.7%) participants did not
highlight any FAQ sentences.
Conclusions: Our preliminary findings suggest that our 2-page form contains the information that most prospective
participants identify as important. Combining simplified forms with supplemental material for those participants who desire
more information could help minimize consent form length and complexity, allowing the most substantively material
information to be better highlighted and enabling potential participants to read the form and ask questions more
effectively.
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Introduction
Advances in genomic research are generating opportunities for
progress toward the vision of ‘‘personalized medicine’’—tailoring
risk reduction, diagnosis, and treatment strategies to individual
patients to improve health, prevent disease, and potentially reduce
healthcare costs [1,2]. A necessary component of such efforts is the
development of key translational research tools [3], including well-
characterized, disease-specific and population-based biospecimen
banks [4].
Research involving biospecimens, however, raises important
issues concerning informed consent. Although the collection,
storage, and research use of biospecimens and data are typically
thought to involve minimal risk [5], information must be conveyed
during the consent process that can be complex or controversial.
Examples include the use of biospecimens and data for future
research that is unspecified at the time of consent; indefinite
storage; ongoing medical record access; contact for future
research; large-scale data sharing; development of commercial
products; privacy and confidentiality protections; participants’
access to research results; and the ability to discontinue
participation.
At the same time, there have been continuing calls for consent
documents to be simplified [6–8]. Consent forms in general have
lengthened over time [9–13]. In addition, although nearly half the
adult population of the U.S. cannot read at higher than an 8th
grade level [14], few consent documents are written at less than a
10th grade level [9–12,15–18]. Not surprisingly, studies have
shown that many participants may not understand the information
disclosed [9,19–21].
Thus, with regard to biorepositories in particular, the National
Cancer Institute’s Office of Biorepositories and Biospecimen
Research has recommended that ‘‘…a 1-page informed consent
document outlining important issues and risks in straightforward
language should be developed and implemented’’ [8]. In response
to this challenge, we developed a simplified biobanking consent
form comprising what we considered to be the minimum
information necessary to meet ethical and regulatory require-
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biobank participants about whether the form included the
information they would find most important to a decision about
taking part in a biobank. Here we describe our form and the
rationale for its content, as well as the results of preliminary testing
with research participants. We conclude by outlining essential next
steps in the development and implementation of a simplified
biobanking consent form.
Methods
Federal policy for the protection of human research subjects,
known as the Common Rule [22], as well as the Health Insurance
Portability and Accountability Act (or ‘‘Privacy Rule’’) [23]
mandate that consent forms be written in plain language that
the subject can understand [24,25]. To reduce the level of
education required to understand our form and to improve its
overall readability (Table 1), we followed basic principles of plain-
language writing, such as choosing common, everyday words;
writing in first person and in active voice; keeping sentences short,
with one main idea per paragraph; using clear organization and
format with descriptive headings; and ensuring adequate white
space and margins [26].
As described below, we incorporated into our form (Exhibit S1;
see Appendix S1 for detailed annotations) the elements of
information required by federal regulations, as well as those
recommended by best practice guidelines for biobanking [5,27–
29].
Purpose
Consent forms must contain a statement that the activity
involves research and an explanation of the purpose of the
research, including the reasons that health information is being
collected. Meeting these requirements in the context of a biobank
is challenging, because the specifics of the future research are not
known at the time of biospecimen collection. Even so, best practice
guidelines [27,28] suggest that the type of research can be
anticipated and described sufficiently—including explicit mention
of the nature and purposes of genetic research—to satisfy federal
regulations. Our consent form addresses these issues in the
introductory text, as well as with a succinct statement of the
motivation for a biobank under the heading ‘‘What Is the Purpose
of This Research Project?’’
Note that our consent form is based on a biobanking model in
which (a) an Institutional Review Board (IRB)-approved protocol
and informed consent are required for the collection and storage of
specimens and data; and (b) researchers proposing to use the
stored materials must submit separate information about their
particular study to an IRB for a determination regarding the
involvement of human subjects [30,31], exemption [32], or a
waiver of the requirement to obtain consent [33]. Because this
model assumes that no studies take place under the biorepository
protocol, our consent form deliberately uses the terms ‘‘research’’
and ‘‘storage project’’ rather than ‘‘study.’’
Procedures
Consent forms must include a description of the procedures to
be followed and identify any procedures that are experimental.
The collection and storage of biospecimens and data for future use
does not involve experimental procedures, but does involve several
steps. We sequenced this information in a generally chronological
fashion to make it easy for subjects to follow [26].
Biospecimen collection. Our form describes collection of
blood through a standard venipuncture procedure.
Information collection. The Privacy Rule and best practice
guidelines [27] require that the explanation of procedures include
a description of the health information to be collected. Our form
delineates three sources of information that will be linked to the
participant’s biospecimen: a questionnaire about basic
demographic information and family health history; ongoing
access to the participants’ medical records; and research data
generated from analyses of the biospecimen.
Access by researchers. Our consent form is consistent with
best practice recommendations [5,27–29] that consent documents
disclose that biospecimens and data will be shared with qualified
researchers; describe the oversight mechanisms that will be used to
ensure that the research is scientifically and ethically appropriate;
and state that identifying information will be removed from
samples and information provided to investigators.
Recontact for additional research. Our form follows best
practice guidelines [27] by disclosing the possibility that
participants may be contacted about taking part in additional
research and providing the option for participants to choose
whether they would be willing to be contacted. We included a limit
on the frequency of such contact, which may be important in
reducing participant burden [34].
Large-scale data sharing. Compared with the procedures
described under ‘‘Access by Researchers,’’ this section of our
consent form discloses sharing that may occur outside the direct
control of the biobank, such as the submission of data from
genome-wide association studies (GWAS) to federal repositories.
Institutions that submit data to the GWAS repository must certify
that the consent documents signed by participants are consistent
with such submission and with subsequent sharing for research
purposes [35].
Duration
The Common Rule requires that subjects be informed of the
expected duration of their participation. The Privacy Rule
similarly requires a statement of how long health information will
be kept, although an authorization expiration date of ‘‘none’’ or
‘‘end of the study’’ are permissible for research, including for the
creation and maintenance of a research database or repository.
Table 1. Consent form readability characteristics
*.
Characteristic Measure Result
Readability Flesch-Kincaid grade level 6.7
Flesch reading ease 71.5
Passive sentences 11%
Complexity Sentences per paragraph 3.1
Words per sentence 13.8
Characters per word 4.3
Length Characters 5322
Words 1188
Sentences 84
Paragraphs 30
Pages (excluding signature page) 2
*Not including title and signature page. Statistics calculated using tools
available in Microsoft Word 2007 (Redmond, WA). Readability tests are based on
the average number of syllables per word and words per sentence. The Flesch
Reading Ease test rates text on a 100-point scale; the higher the score, the
easier it is to understand. The Flesch-Kincaid Grade Level test rates text on a U.S.
school grade level.
doi:10.1371/journal.pone.0013302.t001
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practice for biorepositories [27], subject to sufficient resources and
foreseeable research utility.
Risks
Consent documents must provide a description of any
reasonably foreseeable risks, including, when appropriate, a
statement that there may be some risks that are currently
unforeseeable. The risks associated with biobanking are not
usually physical; rather, they concern the misuse of information,
including clinical and other personal data associated with
specimens, as well as results derived from research using the
specimens. In accordance with best practice guidelines [5,27], our
form discloses possible consequences of such misuse, including
discrimination affecting employment or insurance. Additionally,
because large-scale data sharing occurs outside the control of the
biobank, the risks associated with such sharing are described
separately.
Confidentiality Protections
The Common Rule mandates that consent forms describe the
extent to which confidentiality of records identifying the subject
will be maintained. The Privacy Rule further requires that
prospective participants be told who will use protected health
information. Because the potential harms associated with biobank-
ing are primarily informational, our consent form reflects best
practice [27,28] by explaining that materials will be maintained in
coded form, and by describing who will have access to identifiable
information (a small number of biobank personnel) and who will
not (e.g., researchers who use the stored materials for study). Our
form also notes that there are laws against the misuse of genetic
information [36] but, because DNA is itself a unique identifier, it
also states that confidentiality cannot be guaranteed.
Although ‘‘confidentiality’’ is the technically correct term to
describe the protection of information that has been entrusted to a
biobank, we chose to use ‘‘privacy’’ in its colloquial sense for
greater reading ease.
Benefits and Costs
Consent documents must describe any benefits to the subject or
to others that may reasonably be expected from the research. As
noted in our form, direct personal benefit from biobank
participation is unlikely; rather, the benefits accrue to society at
large if research discoveries are translated into clinical and public
health practice. As per disclosures expected under the Common
Rule, our form states that taking part in the biobank entails no
additional costs to participants or their insurance.
Voluntariness and Alternatives
Federal regulations require a statement that research participa-
tion is voluntary and that persons can refuse without penalty or
loss of benefits to which they are otherwise entitled. Prospective
participants must also be informed about any appropriate
alternatives, which, in the case of a biobank, is simply not to
participate. Our form emphasizes these aspects in the introduction
and in a section titled ‘‘What Are My Options?’’
Discontinuing Participation
According to the Common Rule, consent forms must include a
statement that subjects may stop participating at any time [37].
Similarly, a statement concerning the individual’s right to revoke
the authorization in writing is required under the Privacy Rule
[38].
Discontinuing participation in a biobank is complicated by the
fact that samples and data may have already been transferred to
investigators for specific studies. As per best practice guidelines
[27–29], participants must be allowed to withdraw the remainder of
their specimen (assuming it can be identified via a code), but
samples and data that have been distributed do not necessarily
have to be recalled. In addition to highlighting this limitation, our
consent document alludes to options that could be offered via a
form should a participant wish to withdraw, such as [39,40]:
N No more contact (e.g., to update personal information or
recruit for other research)
N No further medical record access
N Unlink (i.e., remove the link between the code number and
identifying information)
N No further use (i.e., destroy any part of the specimen
remaining)
Questions
As required by the Common Rule, our form instructs
participants who to contact if they have questions about the
research or their rights as research subjects.
Additional Elements
In addition to elements of information required by federal
regulations, best practice guidelines recommend other topics that
should be discussed with prospective biobank participants,
including the possibility that commercial products could be
developed and the availability of research results.
Commercialization. According to best practice guidelines
[27], consent documents should employ clear and specific
language to address the use of stored materials by private or for-
profit entities and the possibility of research leading to the
development of commercial products. Our form notes the
possibility of commercial products in the opening paragraph, as
well as in a statement about payments from any profits under ‘‘Are
There Any Costs or Payments?’’ It also describes a range of
researchers who might access the materials, including researchers
from academic institutions, the government, and industry.
Research results. The Common Rule requires that consent
forms should include, when appropriate, a statement that
significant new findings developed during the course of the
research which may relate to the subject’s willingness to continue
participation will be provided. Perhaps more directly relevant to
biobanks, best practice guidelines [27] call for consent forms to
state whether or not individual or aggregate results will be released
to research participants. As recommended by other groups [5,41],
our form states that participants should not expect to receive
individual results (except in very rare and narrowly defined
circumstances) but that general news about studies being done
through the biobank will be publicly available.
Elements Not Included
We did not include the following information in our simplified
form:
Research-related injury. Consent forms for research
involving more than minimal risk must explain whether any
compensation and/or medical treatment are available if injury
occurs. However, collection and storage of biospecimens and data
are not typically considered to entail risks greater than those
ordinarily encountered in daily life or during the performance of
routine physical exams [5,42].
Simplified Biobanking Consent
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consent forms should note, when appropriate, the approximate
number of subjects involved in the study. Although our form refers
to ‘‘all the other people who take part,’’ the ongoing nature of a
biobank makes stating a precise number difficult and perhaps less
important to a decision about taking part.
Tiered consent. Best practice guidelines suggest that
biorepositories might consider allowing participants to specify
the types of research for which their specimens will be used via a
tiered system of consent. This kind of choice is most easily
implemented when biospecimens are originally collected for
research on a specific condition. In such a case, a binary choice
could be presented between consenting to future research that
condition only, versus on other conditions as well. However, tiered
consent may be inappropriate if the purpose of the biobank—as
reflected in our form—is to provide biospecimens for a broad
range of research, in which case providing participants with a list
of potential types of research would be burdensome and
uninformative [27]. Our form suggests other kinds of choices
that participants could potentially be offered; if implemented,
these would necessitate a robust system to ensure that participants’
stated wishes are followed.
Certificates of confidentiality. Biorepositories may
consider using Certificates of Confidentiality to help protect
identifiable research information from forced disclosure [27].
When in effect, consent forms must contain appropriate language
that describes the protections and limitations a Certificate provides
[43,44].
Results
In addition to satisfying basic regulatory and best practice
requirements using language that is easy to read, we believe the
level of detail provided in a shorter, simpler consent form should
be guided by what a ‘‘reasonable person’’ would want to know in
order to make an informed decision. Thus, after devising our 2-
page document (not including the signature page) as described
above, we recruited a diverse group of diabetes patients from
community-based physician practices in Durham and Kannapolis,
NC. (IRBs for the Duke University Health System and the
Carolinas Medical Center-Northeast Medical Center approved
this research and all participants provided informed consent.) Half
of those recruited (n=56) were randomized to read the 2-page
form, first on paper and then a second time on a tablet computer.
(The other half was assigned to a group that read a longer form
[45].) Participants were encouraged to use ‘‘More information’’
buttons, available in each section of the electronic version on the
tablet computer, whenever they had a question or wanted to know
more (Appendix S2). These buttons led to a series of ‘‘Frequently
Asked Questions’’ (FAQs) that we developed based on the more
detailed information available in a model biobanking consent form
of traditional length (i.e., 6+ pages) [45]. Specifically, for each
sentence in the longer form that was not already represented in the
2-page form, we devised a question that participants might ask to
which that sentence was the answer. Through these FAQs,
participants had access to every sentence they might plausibly see
in a detailed form of traditional length.
Participants were asked to use the computer’s electronic stylus to
highlight specific sentences in the FAQs they thought would be
important if they were considering taking part in a biorepository.
Each participant received the following scripted instruction:
If you look at the answers to any of the Frequently Asked Questions, we
would like to know whether they contain any information that—in your
opinion—would be very important to know about taking part in a
biorepository. If so, please highlight the sentences that have information
that would matter most to you, if you were thinking about taking part in
a biorepository.
In other words, we asked them, in essence, to identify
information that we should consider adding back to our simplified
form.
On average, these participants identified 7 sentences in the
FAQs as important (mean number 6.6, SD 14.7, range: 0–71). No
one sentence was highlighted by a majority of the participants;
thus, no clear mandate emerged for any specific item of
information to be reincorporated into the main body of the
electronic consent form. Further, 34 (60.7%) did not highlight any
sentences in the FAQs, which suggests that these participants felt
the 2-page form already contained the most important informa-
tion. Available evidence indicates that participants at least
considered the other information; on average, they clicked on 5
of the 16 ‘‘More information’’ buttons (mean 4.7, SD 5.1, range:
0–16).
These preliminary results suggest that the simplified form we
had developed contains the information that most prospective
participants identify as important to a decision about taking part in
a biorepository. Obviously, some information not contained in the
2-page form was selected as important by some participants. The
10 sentences most often selected concerned medical record access,
ethics review of proposed studies, information about re-contacting
participants about additional research, privacy risks, and partic-
ipant access to individual research results (Appendix S3; many of
these items have been incorporated into the current version of the
form (Exhibit S1).
Discussion
The President’s Council of Advisors on Science and Technology
[3] recommended the creation of an integrated national network
of standardized biospecimen repositories as well as continued
efforts aimed at developing a standard consent template for the
collection and storage of specimens and data for future research
use.
We produced our form in response to this and other calls for the
simplification of consent documents. Although longer than the 1
page form recommended by NCI [8], we believe our form
comprises the minimum information necessary to meet ethical and
regulatory requirements. Further, it meets our goal of being easier
to read (,7
th grade reading level) and the results of our
preliminary studies suggest that it contains the information that
most prospective participants identify as important.
Clearly, however, informational needs vary at an individual
level; approximately one-third of our participants wanted more
details and there was little agreement on which items of
information should be added to our form. Although we
incorporated those most commonly selected, adding back every
item of information that any individual might find important
would undermine the goal of developing a shorter, simpler
document that focuses on the most substantively relevant
information based on a reasonable person standard. One solution
proposed by those advocating simplified consent is the use of
supplemental materials [6–8]. This approach could help minimize
the length and complexity of the consent form, allowing key
elements to be better highlighted and enabling potential
participants to read the form and ask questions more effectively,
while still providing additional details for those who desire them.
Simplified Biobanking Consent
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someone using a form like ours customize it to convey accurately
the specifics of the research at hand. Regulations and best
practices do not in every instance point to one policy option, and
in these situations, the content of our form represents one possible
approach supported in the literature. However, there may be
other ethically acceptable approaches and the fact that we selected
one as a ‘‘placeholder’’ in our efforts to develop a simplified form
should not be construed as a policy recommendation. For
example:
N NCI Best Practices [27] state the participants should be told
‘‘whether or not’’ they will have access to individual research
results (Recommendation C.2.2.4). The language in our form
sets a high threshold for such release, but some studies may set
a different threshold—particular those that aim to study
participants’ reactions to receipt of results [46].
N Our form suggests that participants who wish to discontinue
participation will be offered various levels of withdrawal, but
some studies may choose not to offer any options other than
destroying the remaining sample, or may not have maintained
a link that would allow the sample to be identified.
N Our form depicts several optional choices for participants, but
a particular study might be designed to offer only some or
none of these choices.
These three examples represent a general principle that applies
to every section: It is essential that each be carefully considered
and modified as needed—ideally with an eye toward maintaining
succinct and simple language—to ensure that it accurately
represents that research for which the form will be used.
Three steps are vital for finalizing a simplified approach to
informed consent for biobanking. First, IRBs and institutional
legal counsel must agree as to the ethical and regulatory sufficiency
of the simplified form, within the context of a complete informed
consent process. Second, there is a critical need for research to
evaluate the simplified form (as compared to a ‘‘traditional’’ length
form)—again, within the context of a complete informed consent
process—with respect to prospective participants’ understanding
of what they are being asked to consent to, their satisfaction with
the amount of information received, and their preference for one
kind of form or another. Third, further study is needed on the
effective use of supplemental materials. As one example, the FAQs
we developed were simply a means by which to present additional
information to participants in our preliminary study for consid-
eration—but it is possible similar FAQs might serve as a useful
format for supplemental material. The effectiveness of this or other
formats in promoting participant understanding and satisfaction,
and the ways that supplemental materials should be incorporated
into the informed consent process are important areas for future
research.
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